Last updated: February 2026
GIP/GLP-1/Glucagon Triple Receptor Agonist • Revolutionary Weight Loss Research
Retatrutide (LY3437943) is a first-in-class triple receptor agonist developed by Eli Lilly. It simultaneously targets three key metabolic pathways: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors.
Retatrutide represents a paradigm shift in metabolic medicine. While semaglutide targets GLP-1 and tirzepatide targets GIP/GLP-1, retatrutide is the first compound to simultaneously activate all three major incretin pathways plus glucagon signaling.
Currently in Phase 3 trials under the TRIUMPH program, retatrutide has shown unprecedented weight loss results - up to 24.2% body weight reduction in Phase 2 studies published in NEJM 2023.
Retatrutide's unique triple mechanism provides synergistic metabolic benefits:
Enhances insulin sensitivity and glucose uptake. Reduces food intake and slows gastric emptying.
Stimulates insulin release, suppresses glucagon, and provides powerful appetite suppression.
Key differentiator: Increases energy expenditure and metabolic rate through hepatic glucose production regulation.
The addition of glucagon receptor activation is what sets retatrutide apart. While GIP/GLP-1 reduce calorie intake, glucagon increases calorie burning by:
The landmark Phase 2 trial demonstrated exceptional efficacy across multiple doses:
| Dose (mg/week) | Weight Loss (%) | Weight Loss (kg) | Duration |
|---|---|---|---|
| 1mg | 7.2% | ~7.5kg | 48 weeks |
| 4mg | 12.9% | ~13.4kg | 48 weeks |
| 8mg | 17.5% | ~18.2kg | 48 weeks |
| 12mg | 24.2% | ~25.2kg | 48 weeks |
Eli Lilly's Phase 3 program includes multiple studies:
Based on clinical trial data, retatrutide follows a careful escalation protocol to minimize side effects:
| Phase | Dose | Duration | Purpose |
|---|---|---|---|
| Initiation | 1mg/week | 4 weeks | GI tolerance, initial response |
| Escalation 1 | 4mg/week | 4-8 weeks | Increased efficacy, side effect monitoring |
| Escalation 2 | 8mg/week | 8-12 weeks | Optimize weight loss response |
| Maximum | 12mg/week | 24+ weeks | Maximum efficacy for responders |
How does retatrutide compare to the current GLP-1 market leaders?
| Compound | Mechanism | Max Weight Loss | FDA Status | Company |
|---|---|---|---|---|
| Semaglutide (Ozempic/Wegovy) | GLP-1 agonist | ~15% (STEP trials) | ✅ Approved | Novo Nordisk |
| Tirzepatide (Mounjaro/Zepbound) | GIP/GLP-1 dual agonist | ~22% (SURMOUNT trials) | ✅ Approved | Eli Lilly |
| Retatrutide | GIP/GLP-1/Glucagon triple agonist | ~24% (Phase 2) | ⏳ Phase 3 (exp. 2026-27) | Eli Lilly |
Retatrutide's superior weight loss may be attributed to glucagon receptor activation, which increases energy expenditure - something semaglutide and tirzepatide cannot do. This creates a dual approach: reduce calories in (GIP/GLP-1) while increasing calories out (glucagon).
Retatrutide typically comes as lyophilized powder in research vials. Proper reconstitution is critical for accuracy:
Retatrutide's side effect profile is similar to other GLP-1 receptor agonists, primarily gastrointestinal:
| Form | Storage Temperature | Shelf Life | Notes |
|---|---|---|---|
| Lyophilized powder | Room temp or refrigerated | 2+ years | Keep away from light and moisture |
| Reconstituted (bac water) | 36-46°F (2-8°C) | 4-6 weeks | Use bacteriostatic water |
| Reconstituted (sterile water) | 36-46°F (2-8°C) | 7-10 days | Shorter shelf life |
| Frozen (reconstituted) | -4°F (-20°C) | 6+ months | May affect potency slightly |
Use our calculator above to determine precise injection volumes for your retatrutide protocol.
↑ Use CalculatorBased on current Phase 3 trial timelines, FDA approval is expected between 2026-2027. Eli Lilly has invested heavily in the TRIUMPH program and appears confident in the compound's prospects.
The 24.2% weight loss seen with retatrutide 12mg approaches that of bariatric surgery (25-35%) but is reversible and doesn't require surgical intervention. This represents a major breakthrough in non-surgical obesity treatment.
Given retatrutide's comprehensive mechanism of action, stacking with other weight loss compounds may increase risk without additional benefit. The triple agonist approach already maximizes the incretin pathway.
Glucagon activation increases metabolic rate and energy expenditure - the "calories out" side of the equation. Previous GLP-1 agonists only addressed "calories in" through appetite suppression. This dual approach may explain retatrutide's superior efficacy.
While pricing isn't confirmed, analysts expect retatrutide to be priced at a premium to tirzepatide (~$1,000-1,500/month) given its superior efficacy and first-in-class status.
Yes, Phase 3 trials include studies in diabetic populations. The GIP/GLP-1 components provide excellent glycemic control, while the glucagon component may help prevent hypoglycemia during weight loss.
Research peptide vendors may carry retatrutide labeled "for research purposes only." Due to its novelty and complexity, availability may be limited and quality varies significantly. Third-party testing is essential.
Phase 1: Completed 2020 (safety, pharmacokinetics)
Phase 2: Completed 2023 (efficacy, optimal dosing)
Phase 3: 2024-2026 (TRIUMPH program)
FDA Filing: Expected late 2026
Approval: Expected 2027
Retatrutide represents the future of obesity medicine. Get notified when new trial data is released.
More Calculators →